Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;8(1):70-74.
doi: 10.15420/aer.2018.71.2.

Introducing Vernakalant into Clinical Practice

Angela Jm Hall  1 , Andrew Rj Mitchell  1
Affiliations
Review

Introducing Vernakalant into Clinical Practice

Angela Jm Hall et al. Arrhythm Electrophysiol Rev. 2019 Mar.

Abstract

Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilitating early discharge from hospital in selected patients in place of electrical cardioversion. The authors explore the data behind vernakalant and discuss how it can be introduced into clinical practice.

Keywords: AF; antiarrhythmic drugs; cardioversion; vernakalant.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Rhythm Control Management of Recent Onset AF
Figure 2:
Figure 2:. Protocol for IV Administration of Vernakalant
See this image and copyright information in PMC

References

    1. Go AS, Hylek EM, Philips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–5. doi: 10.1001/JAMA.285.18.2370. - DOI - PubMed
    1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379:648–61. doi: 10.1016/S0140-6736(11)61514-6. - DOI - PubMed
    1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–9. doi: 10.1016/j.amjcard.2009.07.022. - DOI - PubMed
    1. Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51. doi: 10.1093/eurheartj/eht280. - DOI - PMC - PubMed
    1. Kirchoff P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed

LinkOut - more resources